- Home
- POR vs SYRE Comparison
POR vs SYRE Comparison
Compare POR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | SYRE |
|---|---|---|
| Founded | 1889 | 2013 |
| Country | United States | United States |
| Employees | 2915 | 112 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.5B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | POR | SYRE |
|---|---|---|
| Price | $49.77 | $73.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $48.55 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 1.1M | 927.8K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $3,576,000,000.00 | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $130.58 | ★ N/A |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $39.55 | $13.93 |
| 52 Week High | $54.62 | $78.80 |
Technical Indicators
Market Signals| Indicator | POR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 57.09 |
| Support Level | $47.20 | $67.18 |
| Resistance Level | $51.05 | $76.16 |
| Average True Range (ATR) | 0.78 | 4.12 |
| MACD | 0.23 | -0.97 |
| Stochastic Oscillator | 95.20 | 62.77 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.